Dampak Pemberian Vitamin B1, B6, B12 Parenteral terhadap Proporsi Hiperhomosisteinemia pada Pasien Hemodialisis

Authors

  • Rizaldy Taslim Pinzon Duta Wacana Christian University
  • Kiki Amelia Sanata Dharma University

DOI:

https://doi.org/10.30595/pharmacy.v17i1.4858

Keywords:

gagal ginjal kronis, hemodialisis, hiperhomosisteinemia, vitamin B

Abstract

Banyak pasien gagal ginjal kronis menderita hiperhomosisteinemia yang dapat meningkatkan risiko terjadinya penyakit vaskuler. Dari penelitian sebelumnya ditemukan bahwa pemberian vitamin B dapat mengurangi hiperhomosisteinemia pada pasien yang menjalani hemodialisis. Penelitian ini dilakukan untuk mengukur dampak pemberian vitamin B1, B6, B12 parenteral terhadap proporsi hiperhomosisteinemia pasien gagal ginjal kronik yang menjalani hemodialisis. Penelitian dilakukan dengan desain one group pretest-posttest menggunakan data sekunder rekam medis hasil laboratorium. Data didapatkan dari 117 pasien dengan metode consecutive sampling dan analisis data dilakukan menggunakan SPSS berlisensi dengan uji McNemar. Hasilnya terdapat penurunan proporsi hiperhomosisteinemia yang bermakna setelah pemberian vitamin B selama 2 minggu (70,94%; p=0,000) dan 4 minggu (66,38%; p=0,000), sehingga kesimpulannya, pemberian vitamin B1, B6, dan B12 dalam jangka waktu 2 minggu maupun 4 minggu dapat menurunkan proporsi hiperhomosisteinemia secara bermakna pada pasien gagal ginjal kronis yang menjalani hemodialisis.

References

Abbott. 2017. ARCHITECT Homocysteine [Package Insert]. Illinois: Abbott Laboratories.

Adedokun, O.A. dan Burgess, W.D. 2012. Analysis of paired dichotomous data: a gentle introduction to the mcnemar test in SPSS. Journal of MultiDisciplinary Evaluation, 8 (17):125-131.

AHA. 2019. How High Blood Pressure Can Lead to Kidney Damage or Failure. https://www.heart.org/en/health-topics/high-blood-pressure/health-threats-from-high-blood-pressure/how-high-blood-pressure-can-lead-to-kidney-damage-or-failure. Data diakses pada 17 April 2019.

Aisara, S., Azmi, S., Yanni, M. 2018. Gambaran klinis penderita penyakit ginjal kronik yang menjalani hemodialisis di RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas, 7(1):42-50.

Alexander, N., Matsushita, K., Sang, Y., Ballew, S., Mahmoodi, B.K., Astor, B.C., Coresh, J. 2015. Kidney measures with diabetes and hypertension on cardiovascular disease: the Atherosclerosis Risk in Communities Study. American journal of nephrology, 41(4-5): 409–417.

Amin, H.K., El-Sayed, M.I.K. Leheta, O.F. 2016. Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease. Renal failure, 38(8):1267-1275.

Basheer, M.P., Soopy, K., Pradeep Kumar, K.M., Sreekumaran, E., Ramakrishna, T. 2016. Vitamin B complex and homocysteine status and cognitive impairment in the elderly among Indian population. Journal of Neuroscience and Behavioral Health, 8(4):20-26.

CDC. 2019. Chronic Kidney Disease (CKD) Surveillance System, https://nccd.cdc.gov/CKD/FactorsOfInterest.aspx?type=Age/. Data diakses pada 27 April 2019.

Chao, M.C., Hu, S.L., Hsu, H.S., Davidson, L.E., Lin, C.H., Li, C.I., Liu, C.S., Li, T.C., Lin, C.C. and Lin, W.Y. 2014. Serum homosistein level is positively associated with chronic kidney disease in a Taiwan Chinese population. Journal of nephrology, 27(3):299-305.

Cheng, Y., Huang, R., Kim, S., Zhao, Y., Li, Y., Fu, P. 2016. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: a PRISMA-compliant meta-analysis. Medicine, 95(28):e4167.

Chiu Y.W, Chang, J.M., Hwang, S.J., Tsai, J.C., Chen, H.C. 2009. Pharmacologicaldose of vitamin B12 is as effective as low-dose folinic acidin correcting hyperhomocysteinemia ofhemodialysis patients. Renal Failure, 31(4):278-283.

Cianciolo, G., De Pascalis, A., Di Lullo, L., Ronco, C., Zannini, C., La Manna, G. 2017. Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first. Cardiorenal medicine, 7(4):255-266.

Debreceni, B. dan Debreceni, L. 2014. The role of homocysteine-lowering b-vitamins in the primary prevention of cardiovascular disease. Cardiovascular Therapeutics, 32(3):130-138.

Ganguly, P. dan Alam, S.F. 2015. Role of homocysteine in the development of cardiovascular disease. Nutrition Journal, 14(6):1-10.

Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S., Hobbs, F.D.R. 2016. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE, 11(7):1-18.

Inrig, J. 2010. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis, 23(3):290–297.

JBDS-IP. 2016. Management of Adults with Diabetes on the Haemodialysis Unit. UK: Joint British Diabetes Societies for inpatient care.

Kam, P. dan Power, I. 2015. Principles of Physiology for the Anaesthetist. New York: CRC Press.

Kemenkes RI. 2013. Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.

Kemenkes RI. 2017. InfoDATIN: Situasi Penyakit Ginjal Kronis. Jakarta: Pusat Data dan Informasi Kemenkes RI.

Liu, Y., Ma, X., Zheng, J., Jia, J., Yan, T. 2017. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC nephrology, 18(206):1-11.

Makowski, G.S. 2015. Advances in Clinical Chemistry. Volume 72. Burlington: Academic Press.

Patil, R.G., Bhosle, D.G., Malik, R.A. 2016. Vitamin B12 deficiency in chronic kidney disease. IOSR Journal of Dental and Medical Sciences, 15(9):22-25.

Pranandari, S. dan Supadmi, W. 2015. Faktor risiko gagal ginjal kronik di Unit Hemodialisis RSUD Wates Kulon Progo. Majalah Farmaseutik, 11 (2):316-320.

Sahu, A., Gupta, T., Kavishwar, A., Singh, R.K. 2015. Cardiovascular diseases risk prediction by homocysteine in comparison to other markers: a study from Madhya Pradesh. Journal of the Association of Physicians of India, 63:37-40.

Saposnik, G., Ray, J.G., Sheridan, P., McQueen, M., Lonn, E. and HOPE 2 Investigators. 2009. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke, 40(4):1365-1372.

Sharma, S. 2014. Nursing Research and Statistics. India: Reed Elsevier India Private Limited.

Sullivan, K.M. 2019. Sample Size for a Proportion or Descriptive Study. https://www.openepi.com/SampleSize/SSPropor.htm. Data diakses pada 17 Januari 2019.

Surahman, Rachmat, M., Supardi, S. 2016. Modul Bahan Ajar Cetak Farmasi: Metodologi Penelitian. Jakarta: Kemenkes RI.

Tayebi, A., Biniaz, V., Savari, S., Ebadi, A., Shermeh, M.S., Einollahi, B., Rahimi, A. 2016. Effect of vitamin B 12 supplementation on serum homocysteine in patients undergoing hemodialysis: a randomized controlled trial. Saudi Journal of Kidney Diseases and Transplantation, 27(2):256-262.

Venancio, L.D.S., Burini, R.C., Yoshida, W.B. 2010. Dietary treatment of hyperhomocysteinemia in peripheral arterial disease. Jornal Vascular Brasileiro, 9(1):28-41.

Webster, A.C., Nagler, E.V., Morton, R. L., Masson, P. 2017. Chronic Kidney Disease. The Lancet, 389 (10075):1238-1252.

WHO. 2019. Diabetes Programme. https://www.who.int/diabetes/action_online/basics/en/index3.html. Data diakses pada 18 April 2019.

Downloads

Published

2020-07-08

How to Cite

Pinzon, R. T., & Amelia, K. (2020). Dampak Pemberian Vitamin B1, B6, B12 Parenteral terhadap Proporsi Hiperhomosisteinemia pada Pasien Hemodialisis. PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), 17(1), 41–53. https://doi.org/10.30595/pharmacy.v17i1.4858

Similar Articles

<< < > >> 

You may also start an advanced similarity search for this article.